gadavist Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Gadavist, and what generic alternatives are available?
Gadavist is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in GADAVIST is gadobutrol. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the gadobutrol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gadavist
A generic version of gadavist was approved as gadobutrol by HENGRUI PHARMA on November 17th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for gadavist?
- What are the global sales for gadavist?
- What is Average Wholesale Price for gadavist?
Summary for gadavist
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 30 |
| Clinical Trials: | 28 |
| Patent Applications: | 410 |
| Drug Prices: | Drug price information for gadavist |
| What excipients (inactive ingredients) are in gadavist? | gadavist excipients list |
| DailyMed Link: | gadavist at DailyMed |
Recent Clinical Trials for gadavist
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Lipella Pharmaceuticals, Inc. | Early Phase 1 |
| Christopher J Chermansky, MD | Early Phase 1 |
| National Institutes of Health (NIH) | Early Phase 1 |
Pharmacology for gadavist
| Drug Class | Gadolinium-based Contrast Agent |
| Mechanism of Action | Magnetic Resonance Contrast Activity |
US Patents and Regulatory Information for gadavist
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | GADAVIST | gadobutrol | SOLUTION;INTRAVENOUS | 201277-006 | Dec 18, 2013 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bayer Hlthcare | GADAVIST | gadobutrol | SOLUTION;INTRAVENOUS | 201277-003 | Mar 14, 2011 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bayer Hlthcare | GADAVIST | gadobutrol | SOLUTION;INTRAVENOUS | 201277-001 | Mar 14, 2011 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bayer Hlthcare | GADAVIST | gadobutrol | SOLUTION;INTRAVENOUS | 201277-002 | Mar 14, 2011 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bayer Hlthcare | GADAVIST | gadobutrol | SOLUTION;INTRAVENOUS | 201277-005 | Mar 14, 2011 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bayer Hlthcare | GADAVIST | gadobutrol | SOLUTION;INTRAVENOUS | 201277-004 | Mar 14, 2011 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for gadavist
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | GADAVIST | gadobutrol | SOLUTION;INTRAVENOUS | 201277-006 | Dec 18, 2013 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Hlthcare | GADAVIST | gadobutrol | SOLUTION;INTRAVENOUS | 201277-003 | Mar 14, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Hlthcare | GADAVIST | gadobutrol | SOLUTION;INTRAVENOUS | 201277-004 | Mar 14, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Hlthcare | GADAVIST | gadobutrol | SOLUTION;INTRAVENOUS | 201277-005 | Mar 14, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Hlthcare | GADAVIST | gadobutrol | SOLUTION;INTRAVENOUS | 201277-002 | Mar 14, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| Bayer Hlthcare | GADAVIST | gadobutrol | SOLUTION;INTRAVENOUS | 201277-001 | Mar 14, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for gadavist
See the table below for patents covering gadavist around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Israel | 97592 | Tetraazacyclododecane butyltriol derivatives processes for the production thereof and pharmaceutical compositions containing the same | ⤷ Sign Up |
| Spain | 2074219 | ⤷ Sign Up | |
| Canada | 2038493 | 1,4,7,10-TETRAAZACYCLODODECANE BUTYLTRIOLS (1,4,7,10-TETRAAZACYCLODODECANE BUTYLTRIOLS) | ⤷ Sign Up |
| Hungary | T60478 | ⤷ Sign Up | |
| Japan | H05320146 | PREPARATION OF 1,4,7,10-TETRAAZACYCLO- DODECANE-BUTYLTRIOL, ITS GADOLINIUM COMPLEX, PHARMACEUTICAL PRODUCT AND DIAGNOSTIC AGENT CONTAINING THIS AND ITS COMPOUND AND PREPARATION OF PHARMACEUTICAL PRODUCT | ⤷ Sign Up |
| Ireland | 67643 | 1,4,7,10-tetraazacyclodedecane butyltriols processes for their production and pharmaceutical agents containing them | ⤷ Sign Up |
| Norway | 911063 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for gadavist
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0448191 | CA 2001 00009 | Denmark | ⤷ Sign Up | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
